mRNA Influenza Vaccine Shows Superior Efficacy in Older Adults
A study published earlier this year in the New England Journal of Medicine indicates that the mRNA-1010 influenza vaccine offers more effective protection against illness in adults aged 50 and older compared to standard vaccines. Clinical data revealed that confirmed influenza-like illness affected 2.0% of mRNA-1010 recipients, contrasted with 2.8% of comparator recipients, yielding a relative vaccine efficacy of 26.6%.
For adults aged 65 and older, efficacy results were slightly higher at 27.4%. Study authors concluded that the mRNA-1010 vaccine proved superior to licensed standard-dose vaccines in preventing reverse-transcription polymerase chain reaction (RT-PCR)–confirmed, protocol-defined influenza-like illness within this demographic.
The findings carry significant public health implications, given that older populations face heightened risks of severe complications, hospitalizations, and mortality from the flu each year. According to Centers for Disease Control and Prevention (CDC) data from the 2023–24 respiratory season, adults 65 and older accounted for 68% of flu-related deaths and 50% of hospitalizations, while individuals aged 50 to 64 accounted for 20% of hospitalizations and deaths.
Researchers note that mRNA technology allows for a faster manufacturing timeline—taking roughly three to four months compared to the eight to nine months required for traditional vaccines—giving public health officials a better window to target circulating strains. Experts also emphasize ongoing efforts to address mRNA vaccine hesitancy by clarifying safety profiles, dispelling DNA alteration myths, and highlighting decades of prior research.
